Prelude Therapeutics Inc Cash And Cash Equivalents At Carrying Value

Quick Answer

Prelude Therapeutics Inc reported Cash And Cash Equivalents At Carrying Value of $35.26 million for the year ending 2025.

  • Prelude Therapeutics Inc showed an increase of +182.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Prelude Therapeutics Inc's annual report (Form 10-K), filed with the SEC on March 10, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Prelude Therapeutics Inc's Cash And Cash Equivalents At Carrying Value has grown by 86.7%.
  • Historical annual values: Fiscal year 2025: $35.26 million | Fiscal year 2024: $12.47 million | Fiscal year 2023: $25.29 million | Fiscal year 2022: $30.61 million | Fiscal year 2021: $31.83 million | Fiscal year 2020: $218.31 million | Fiscal year 2019: $18.88 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: